The use of artificial intelligence (AI) in drug development has been hyped up for some time now – and the COVID-19 pandemic is finally a chance for these technologies to prove their worth.
COVID-19 casts a spotlight on the need for healthcare providers to interact with people virtually, address the affordability crisis compounded by the pandemic, and alleviate the challenges
Digital transformation has long been a priority for all life science companies and it has been made even more pressing by the current health emergency caused by COVID-19.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
